Literature DB >> 23549086

Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Barbara Onnis1, Nicole Fer, Annamaria Rapisarda, Victor S Perez, Giovanni Melillo.   

Abstract

IL-11 and its receptor, IL-11Ra, are expressed in human cancers; however, the functional role of IL-11 in tumor progression is not known. We found that IL11 is a hypoxia-inducible, VHL-regulated gene in human cancer cells and that expression of IL11 mRNA was dependent, at least in part, on HIF-1. A cooperative interaction between HIF-1 and AP-1 mediated transcriptional activation of the IL11 promoter. Additionally, we found that human cancer cells expressed a functional IL-11Ra subunit, which triggered signal transduction either by exogenous recombinant human IL-11 or by autocrine production of IL-11 in cells cultured under hypoxic conditions. Silencing of IL11 dramatically abrogated the ability of hypoxia to increase anchorage-independent growth and significantly reduced tumor growth in xenograft models. Notably, these results were phenocopied by partial knockdown of STAT1 in a human prostate cancer cell line (PC3), suggesting that this pathway may play an important role in mediating the effects of IL-11 under hypoxic conditions. In conclusion, these results identify IL11 as an oxygen- and VHL-regulated gene and provide evidence of a pathway "hijacked" by hypoxic cancer cells that may contribute to tumor progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549086      PMCID: PMC3613900          DOI: 10.1172/JCI59623

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Hypoxia and cancer.

Authors:  Gregg L Semenza
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.

Authors:  Erika Terzuoli; Maura Puppo; Annamaria Rapisarda; Badarch Uranchimeg; Liang Cao; Angelika M Burger; Marina Ziche; Giovanni Melillo
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

Review 3.  More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer.

Authors:  Tracy Putoczki; Matthias Ernst
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

4.  Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells.

Authors:  Toshiyuki Nakayama; Ayumi Yoshizaki; Seiya Izumida; Tomoyuki Suehiro; Shiro Miura; Takashi Uemura; Yuichi Yakata; Kazuko Shichijo; Shunichi Yamashita; Ichiro Sekin
Journal:  Int J Oncol       Date:  2007-04       Impact factor: 5.650

5.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.

Authors:  Kurt J Sales; Vivien Grant; Ian H Cook; David Maldonado-Pérez; Richard A Anderson; Alistair R W Williams; Henry N Jabbour
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

6.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

Authors:  Julia Bollrath; Toby J Phesse; Vivian A von Burstin; Tracy Putoczki; Moritz Bennecke; Trudie Bateman; Tim Nebelsiek; Therese Lundgren-May; Ozge Canli; Sarah Schwitalla; Vance Matthews; Roland M Schmid; Thomas Kirchner; Melek C Arkan; Matthias Ernst; Florian R Greten
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

Review 7.  Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.

Authors:  Annamaria Rapisarda; Giovanni Melillo
Journal:  Drug Resist Updat       Date:  2009-04-25       Impact factor: 18.500

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.

Authors:  Matthias Ernst; Meri Najdovska; Dianne Grail; Therese Lundgren-May; Michael Buchert; Hazel Tye; Vance B Matthews; Jane Armes; Prithi S Bhathal; Norman R Hughes; Eric G Marcusson; James G Karras; Songqing Na; Jonathon D Sedgwick; Paul J Hertzog; Brendan J Jenkins
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples.

Authors:  Valerae O Lewis; Michael G Ozawa; Michael T Deavers; Guiying Wang; Tomo Shintani; Wadih Arap; Renata Pasqualini
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more
  31 in total

1.  Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer.

Authors:  Chuanli Ren; Yong Chen; Chongxu Han; Deyuan Fu; Hui Chen
Journal:  Tumour Biol       Date:  2014-08-16

2.  Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-β pathways in MCF-7 Cancer cells with PX-866 and Raloxifene.

Authors:  Gregory W Peek; Trygve O Tollefsbol
Journal:  Exp Cell Res       Date:  2016-03-23       Impact factor: 3.905

3.  The TIP60 Complex Is a Conserved Coactivator of HIF1A.

Authors:  Joel I Perez-Perri; Veronica L Dengler; K Audrey Audetat; Ahwan Pandey; Elizabeth A Bonner; Marjeta Urh; Jacqui Mendez; Danette L Daniels; Pablo Wappner; Matthew D Galbraith; Joaquín M Espinosa
Journal:  Cell Rep       Date:  2016-06-16       Impact factor: 9.423

4.  Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).

Authors:  Xing Liu; Xiaolian Cai; Bo Hu; Zhichao Mei; Dawei Zhang; Gang Ouyang; Jing Wang; Wei Zhang; Wuhan Xiao
Journal:  J Biol Chem       Date:  2016-10-24       Impact factor: 5.157

5.  Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.

Authors:  Wei Zhou; Wei Sun; Mingo M H Yung; Sheng Dai; Yihua Cai; Chi-Wei Chen; Yunxiao Meng; Jennifer B Lee; John C Braisted; Yinghua Xu; Noel T Southall; Paul Shinn; Xuefeng Huang; Zhangfa Song; Xiulei Chen; Yan Kai; Xin Cai; Zongzhu Li; Qiang Hao; Annie N Y Cheung; Hextan Y S Ngan; Stephanie S Liu; Stephanie Barak; Jing Hao; Zhijun Dai; Alexandros Tzatsos; Weiqun Peng; Huadong Pei; Zhiyong Han; David W Chan; Wei Zheng; Wenge Zhu
Journal:  Oncogene       Date:  2018-04-17       Impact factor: 9.867

Review 6.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Authors:  M Buchert; C J Burns; M Ernst
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

Review 7.  The role of HIF1α in renal cell carcinoma tumorigenesis.

Authors:  Lorraine J Gudas; Leiping Fu; Denise R Minton; Nigel P Mongan; David M Nanus
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

8.  Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells.

Authors:  Gregory W Peek; Trygve O Tollefsbol
Journal:  J Cell Biochem       Date:  2015-12-28       Impact factor: 4.429

9.  DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.

Authors:  Ziyue Chen; Xu Chen; Ruihui Xie; Ming Huang; Wen Dong; Jinli Han; Jingtong Zhang; Qianghua Zhou; Hui Li; Jian Huang; Tianxin Lin
Journal:  Mol Ther       Date:  2019-01-09       Impact factor: 11.454

10.  A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.

Authors:  Caitlin M Tice; Crystal Tran; Michael L Beshiri; Holly M Nguyen; Adam G Sowalsky; Supreet Agarwal; Keith H Jansson; Qi Yang; Kerry M McGowen; JuanJuan Yin; Aian Neil Alilin; Fatima H Karzai; William L Dahut; Eva Corey; Kathleen Kelly
Journal:  Clin Cancer Res       Date:  2018-05-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.